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Abstract 
Background: Bipolar disorder is a severe and heterogeneous mental disorder. Despite great advances in neurosci-
ence over the past decades, the precise causative mechanisms at the transmitter, cellular or network level have so far 
not been unraveled. As a result, individual treatment decisions cannot be tailor-made and the uncertain prognosis is 
based on clinical characteristics alone. Although a subpopulation of patients have an excellent response to pharma-
cological monotherapy, other subpopulations have been less well served by the medical system and therefore require 
more focused attention. In particular individuals at high risk of bipolar disorder, young patients in the early stages 
of bipolar disorder, patients with an unstable highly relapsing course and patients with acute suicidal ideation have 
been identified as those in need.
Structure: A research consortium of ten universities across Germany has therefore implemented a 4 year research 
agenda including three randomized controlled trials, one epidemiological trial and one cross-sectional trial to address 
these areas of unmet needs. The topics under investigation will be the improvement of early recognition, specific 
psychotherapy, and smartphones as an aid for early episode detection and biomarkers of lithium response. A subset 
of patients will be investigated utilizing neuroimaging (fMRI), neurophysiology (EEG), and biomaterials (genomics, 
transcriptomics).
Conclusions: This article aims to outline the rationale, design, and methods of these individual studies.
Keywords: Bipolar disorder, Randomized controlled trial, Research consortium, Psychotherapy, Early recognition, 
Ambulatory monitoring, BipoLife
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Background
Bipolar disorder is a severe and recurrent mental disor-
der ranked among the leading causes of disability. The 
condition has a high degree of heritability (Kieseppa et al. 
2004) and is associated with poor social and occupational 
outcomes, high rates of morbidity and mortality and is 
considered to be one of the disorders with the highest 
risk of suicide (Chen and Dilsaver 1996). Although there 
have been great advances in the understanding of mental 
disorders in general, the precise mechanisms underly-
ing bipolar disorder and the response to treatment at the 
genetic, cellular or neuroanatomical level remain elusive.
The heterogeneity of the disorder and the complex-
ity of its neurobiological underpinnings require an inte-
grated multicentre approach to research, utilizing diverse 
research strategies and harvesting the access to substan-
tial patient numbers that could not be recruited at a sin-
gle site alone.
The consortium of ten university hospitals described 
in this article has defined areas of unmet needs in 
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prevention, diagnosis and therapeutic intervention for 
four subgroups of patients: individuals at high risk of 
bipolar disorder, young patients in the early stages of 
bipolar disorder, patients with an unstable highly relaps-
ing course, and patients with acute suicidal ideation.
While a subgroup of patients with bipolar disorder 
responds excellently to lithium monotherapy, treatment 
response remains inadequate for most and no biomark-
ers exist to guide a rational choice of treatment (Kessing 
et  al. 2011). A fifth project within the consortium will 
therefore attempt to identify genomic, transcriptomic, 
and proteomic markers of lithium response.
Three randomized controlled trials (RCTs), one epide-
miological trial, and one cross-sectional trial investigat-
ing biomaterials will be supported by two translational 
platforms supplying the infrastructure for multicentre 
data-management, bio banking, electroencephalography, 
and neuroimaging. The consortium incorporates nine 
German university hospitals (Dresden, Berlin, Munich, 
Frankfurt, Marburg, Hamburg, Bochum, Tubingen, and 
Heidelberg) and the medical informatics section of Got-
tingen University.
The networks 4 year funding period by the German 
ministry of education (BMBF) began in 2015.
Each project will be introduced by outlining the ration-
ale, the questions the study will attempt to clarify, and a 
synopsis of the study protocol.
Improving early recognition and intervention in people 
at‑risk of developing bipolar disorder (Project A1)
A large proportion of patients with bipolar disorder (BD) 
experience substantial symptomatology months or even 
years before full BD manifestation (Lish et  al. 1994). 
Studies have repeatedly demonstrated a significant delay 
until adequate diagnosis and treatment, estimated to be 
app. 10 years on average (Baldessarini et  al. 2003; Pfen-
nig et al. 2011). Treatment delay is associated with a poor 
functional outcome and an elevated risk of suicide (Post 
et  al. 2010). Delaying the initiation of lithium is equally 
associated with a poorer response (Kessing et  al. 2014). 
Prolonged periods of undetected illness with no or inad-
equate treatment leading to significant psychosocial 
impairment therefore necessitate improved instruments 
and guidelines for early identification and intervention so 
as to advance overall disease management.
So far there are no evidence-based guidelines for pri-
mary or secondary prevention of BD. Only a few small 
interventional studies investigating pharmacological 
interventions (placebo-controlled trials: lithium (Geller 
et  al. 1998), valproic acid (Findling et  al. 2007) or fam-
ily focused psychotherapy (Miklowitz et  al. 2011; Mik-
lowitz et al. 2013; Nadkarni and Fristad 2010) have been 
conducted, with results that are insufficiently reliable 
because of several limitations, particularly insufficient 
power, and the lack of an adequate control condition 
within the psychotherapy trials.
Due to its high heritability a positive family history 
remains as one of the major risk factors for BD. In off-
spring of parents with BD, there is evidence that anxiety 
is an antecedent of subsequent mood episodes (Duffy 
et  al. 2007). Furthermore, clinical, epidemiological, 
and genetic data suggest that the risk to develop BD is 
increased in at least a subgroup of patients with ADHD 
(Duffy 2012), and a diagnosis of substance abuse, insom-
nia (Ritter et al. 2015) and a history of stressful life events 
may be precursors of subsequent BD. Among patients 
with single or recurrent depression, certain psychopatho-
logical markers (i.e., suicidality and diurnal variation) are 
associated with a higher incidence of ensuing manic epi-
sodes (Pfennig et al. 2016).
Early recognition and risk stratification efforts began in 
the domain of psychotic disorders and have only recently 
been expanded to BD. Preliminary structured instru-
ments have been developed to map potential risk factors, 
quantify the risk, and evaluate the predictive power for 
conversion prospectively (BPSS-P, EPIbipolar, BAR cri-
teria) (Correll et  al. 2014; Leopold et  al. 2012; Bechdolf 
et al. 2012) and attempts are being made to identify reli-
able biomarkers (Duffy et al. 2014). The available limited 
prospective data in small samples need to be substanti-
ated by a longitudinal approach in larger at-risk cohorts. 
Furthermore, resilience factors (i.e., emotion regulation 
processes) have received very little attention so far.
Project A1 therefore aims to address the following 
questions:
a. What is the predictive power of individual risk fac-
tors and risk constellations in defined risk groups for 
BD in the age group 15–35 and in a representative 
cohort using the different existing instruments/crite-
ria?
b. What are resilience factors that lower the risk for BD 
in the proposed age group?
c. What is the association of fluid/non-fluid biomarkers 
and neuroimaging data with clinical outcome?
d. How can the information from (a), (b), and (c) be 
integrated for further development of the diagnostic 
tools and harmonization of the diagnostic process 
across centers?
e. What factors describe and/or influence the pro-
cess of treatment decision-making in this naturalis-
tic setting? What are the efficacy (acute/preventive 
effects) and tolerability/safety measures of treatment 
approaches in at-risk subjects?
f. What information from (e) can be used to refine a 
proposed category model & treatment guidance?
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We are conducting a multicentre, prospective, natu-
ralistic cohort study with a follow-up of ≥24 months per 
individual. Three groups are being studied: (a) Help-seek-
ing youth and young adults aged 15–35 without a diagno-
sis of BD consulting early detection centers & specialized 
services with  ≥1 proposed risk factor for BD; (b) In-/
outpatients with a depressive episode aged 15–35; (c) In-/
outpatients with ADHD aged 15–35.
As reference group for the frequency of the potential 
risk factors, the German IMAGEN cohort, a representa-
tive population cohort, is being assessed. The cohort was 
first assessed at age 14 and 16 and is currently being re-
assessed at age 18–20.
All participants will receive state of the art counseling 
and treatment according to their individual needs. This 
will encompass general preventive measures, specific 
preventive measures, psychotherapy, and/or pharmaco-
therapy. The assessments utilized will include a detailed 
description of current and socioeconomic circumstances, 
the above-mentioned instruments to assess risks of sub-
sequent BD and instruments to assess resilience, psy-
chosocial functioning, and comorbidities. The baseline 
assessment will be followed by biannual follow-ups for a 
minimum of 2 years. Participants will receive the option 
of participating in the imaging, EEG, and genomics stud-
ies (technical platform projects, TPP1 and TPP2) with 
the aim of identifying potential neuroimaging, neuro-
physiological, and genomic markers for the prediction of 
subsequent conversion to bipolar disorder. The details of 
the methods and paradigms used are described in section 
TPP1 and TPP2.
The statistical assumptions for the two main hypoth-
eses are as follows: Hypothesis 1 Over a period 
of ≥24 months, ≥15% of at-risk individuals will develop 
a first (hypo)manic episode. The assumption of a 15% 
conversion rate is generally considered conservative. 
Hypothesis 2 Specific risk factors or risk factor constella-
tions will be predictive of mania development during the 
observation period. We will test this hypothesis in vari-
ous ways. First, univariate analyses will be run to deter-
mine individual predictors of conversion to BP-I. Second, 
we will conduct a multivariate logistic regression model 
to determine risk factor constellations that are predictive 
of mania with each individual factor also being significant 
within the model. In addition to the logistic regression 
model approach, this hypothesis will also be tested using 
survival analysis-based Cox regression analyses to pre-
dict time to onset of first mania, recognizing that individ-
uals will have variable follow-up times. All analyses will 
use a backward selection approach to ascertain variables 
that have unique predictive associations with conversion 
at an initially liberal threshold of p  ≤  0.10. After that, 
omnibus regression will be conducted in which variables 
found to contribute uniquely to conversion in the initial 
series will be considered together. Variables that remain 
significant at p < 0.05 in the omnibus analysis will then be 
tested for multiplicative (interaction) effects in relation 
to conversion. Finally, the identified risk factor(s) will be 
tested regarding their predictive power, calculating sensi-
tivity, specificity, positive predictive value, negative pre-
dictive value, and accuracy (e.g., applying ROC analyses). 
With ≥75 converters (≥15% of n = 500 of risk group I), 
we expect to have >80% power for this model testing. For 
risk group II, we expect about 4% and for risk group III 
5% converters (given a comorbidity rate of about 15%). 
Formal sample size estimation will be carried out at a 
pre-planned interim analysis at inclusion of 50% of each 
risk group into the study. If needed, sample sizes will be 
adjusted. From the IMAGEN sample, approx. 200 indi-
viduals will be included to provide data on the frequency 
of potential risk factors in this representative population 
sample.
The outcomes will help to guide future early recogni-
tion and intervention by providing a more detailed and 
reliable approach to psychiatric risk stratification.
Adjuvant psychotherapy in early stage bipolar disorder 
(Project A2)
Young bipolar patients (<35 years.) experience the high-
est personal cost (social, professional, personal) and 
elevated rates of attempted or completed suicide during 
the early course of the illness (Perlis et al. 2004). Recent 
meta-analyses of available clinical trials have concluded 
that there is limited availability of psychotherapy stud-
ies in bipolar disorder patients in general, and no stud-
ies exist which have focused on specific subgroups of 
patients, in particular young adults in the early course of 
the disorder. However, retrospective data in psychologi-
cal intervention studies have shown significantly larger 
effects in patients during early stages of bipolar disor-
der who had experienced fewer affective episodes (Scott 
et  al. 2007; Meyer and Hautzinger 2012; Reinares et  al. 
2010). In addition, no intervention study has yet been 
conducted using neuroimaging methods to identify both 
predictive factors and neural correlates of successful 
psychotherapy.
The goal of the proposed randomized controlled trial, 
which involves 300 younger patients with bipolar disor-
der in remission, is to test hypothesis that the addition 
of a specific psychotherapy (SEKT) to psychiatric care 
(TAU) in comparison to an active (supportive) control 
treatment (FEST) will lead to positive outcomes such 
as reduced relapse rates, missed days at work/school, 
days spent in hospitals, and health costs; significantly 
improved treatment compliance and social function-
ing. Participants will receive the option of participating 
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in a neuroimaging study which aims to test the hypoth-
esis that specific psychotherapy (SEKT) will have a more 
robust effect on neural networks (amygdala, medial pre-
frontal activation) associated with emotion regulation 
and social cognition compared to FEST.
Intervention and follow‑up
Patients between 18 and 35  years of age suffering from 
bipolar disorder I or II with at least one episode during 
the preceding 2 years will be eligible for the trial. Partici-
pants are required to be in stable remission and in regu-
lar medical care, including mood stabilizing medication.
300 patients will be randomized to either SEKT (exper-
imental condition) or FEST (active control condition) 
and represent the intention-to-treat sample. All included 
subjects (n  =  300) will be re-assessed at 6, 12, and 
18 months after intake. The recruitment and implemen-
tation of therapy will occur at nine clinical sites across 
the BipoLife consortium.
A new format for patients will be used to deliver both 
treatment approaches. Over 4  months, 4 full-day work-
shop-style group treatments with 4–7 patients will be 
offered by 1–2 specially trained therapists under expert 
supervision. In the past, this format has proven popular 
among patients, especially when conducted at weekends, 
since it is more compatible with occupational or educa-
tional schedules.
The SEKT intervention includes elements of cogni-
tive behavior therapy (Lam et  al. 2005), interpersonal 
and social rhythm therapy (Frank et  al. 2005), family 
focused behavior therapy (Miklowitz 2012), mindfulness 
based therapy (van der Velden et al. 2015), and psychoe-
ducation (Colom et al. 2009). In addition, a new element 
“emotion and impulsivity regulation skills” will be added. 
The FEST condition includes general supportive meas-
ures and positive feedback, and allows for a more flexible, 
albeit patient-centered approach.
Relapse will be assessed every 6  months by “Longitu-
dinal follow-up evaluation” (LIFE) (Keller et  al. 1987), 
a structured interview leading to reliable information 
about course of illness, time in remission, development 
of new affective episodes (relapse), and comorbidity. In 
addition, measurements of symptomatology (QIDS-C & 
QIDS-SR, YMRS, ASRM) (Rush et al. 2003; Young et al. 
1978; Altman et al. 1997), social functioning and quality 
of life (GAF, FAST) (Hall 1995; Rosa et al. 2007) will be 
assessed. The trial aims to recruit at least 100 participants 
for the optional neuroimaging study. The paradigms 
(described in detail in TPP2) will be carried out prior to 
and following the therapeutic intervention.
The primary efficacy endpoint has been defined as fol-
lows: “Relapse” to a new affective (depressive, manic or 
mixed) episode. This will include a calculation of “relapse 
rate” and “time to relapse” (days after inclusion to study) 
assessed by clinician blind to treatment condition using 
longitudinal follow-up evaluation interview (LIFE) every 
6  months. Secondary endpoints will include medica-
tion compliance (blood serum level), medication adverse 
effects, days missed at work/school, and social function-
ing level. Time until relapse will be addressed by non-par-
ametric survival analyses involving logRank or Wilcoxon 
statistics and sensitivity analyses for the subgroups ITT 
and PP. The time-dependent evolution of group-specific 
hazard rates will be investigated by parametric models 
addressing differences in the dynamics of relapse in both 
arms. Cox regressions will be performed for the prob-
ability of relapse and time until relapse if the proportional 
hazards assumption will not be negated. Sample size 
calculations refer to a logRank statistic under α  =  0.05 
and β  =  0.2 (80% power) under the assumptions of (a) 
an accrual time of 24 months, (b) a total study duration 
of 48 months, and (c) a drop-out rate of 12% (the latter 
based on experiences from previous studies). We have 
defined a treatment effect of factor 2 as a relevant effect, 
i.e., a hazard ratio (HR) of 0.5. The results, if positive, will 
ideally improve psychotherapeutic content and delivery 
for young patients in the early stages of bipolar disorder.
Smartphone‑based ambulatory assessment of early 
warning signs, including personalized real‑time 
data‑driven therapeutic interventions, in the long‑term 
treatment of bipolar disorders. A randomized controlled 
trial (Project A3)
In general, manic and depressive episodes develop dur-
ing a period of several days to weeks (Strauss et al. 2012). 
Preventing new episodes is one of the main goals of long-
term treatment. To improve early intervention, effective 
detection of emerging symptoms heralding an immi-
nent episode (early warning signs) is crucial. According 
to a recent Cochrane review, self-help and psychologi-
cal treatments that teach patients, alongside other psy-
chological interventions, to recognize and manage early 
warning signs have been shown to delay time to a new 
affective episode (Morriss et al. 2007). Since the intervals 
between visits to the treating psychiatrist are usually long 
during periods of euthymia, the responsibility to detect 
early warning signs lies largely with patients themselves. 
Monitoring affective symptoms, not to miss early warn-
ing signs, is typically accomplished with the assistance of 
mood charting, which, however, has inherent limitations 
in clinical practice. On the one hand the symptoms of the 
disorder frequently interfere with patients’ introspective 
assessment, particularly in the case of emerging mania. 
On the other hand, the daily documentation becomes 
tedious during periods of euthymia and is then frequently 
discontinued.
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Smartphones have become a ubiquitous feature of 
everyday life. In 2015, there were an estimated 46 mil-
lion smartphone users in Germany, 42 million in the UK, 
and 2.08 billion users worldwide. (http://www.statista.
com/statistics/). Smartphone-based ambulatory assess-
ment (SBAA), including real-time data capture of DSM-5 
bipolar disorder symptoms and data-driven, individual 
threshold-defined therapeutic interventions (SBAA+), 
represents a promising approach to overcome the limi-
tations of conventional mood charting. The underly-
ing principle is that several parameters of smartphone 
usage which are likely to be influenced by current psy-
chopathology (GPS, acceleration sensor, communica-
tion patterns) are registered automatically via embedded 
software (Ebner-Priemer et  al. 2013), encrypted and 
transferred to a secure server for real-time analysis. The 
underlying analyzing algorithm will be informed by pre-
vious studies and will utilize the participant’s individual 
baseline recorded during a period of euthymia as founda-
tion. Patterns breaching the predefined threshold that are 
compatible with an evolving mood episode can thereby 
be identified automatically.
The consortium will conduct a randomized, multi-
center, observer-blind, parallel group controlled trial 
with a 78 week (18 month) intervention phase. Five cent-
ers across the network will be participating. The primary 
hypothesis states that continuous ambulatory real-time 
monitoring of early warning signs for new depressive or 
(hypo)manic episodes by smartphone-based technology 
including feedback to the treating physician (SBAA+), 
will prolong time to a new mood episode and reduce hos-
pitalizations (intervention group). In the control group 
ambulatory monitoring of early warning signs for emerg-
ing depressive or (hypo)manic episodes will occur in an 
identical manner, but the results will not be transmit-
ted to the treating psychiatrist. The aim is to recruit 180 
patients with bipolar disorder for a stabilization phase of 
up to 6  months. Only those able to maintain euthymia 
for 4 successive weeks (app. 120) will be randomized to 
either SBAA+  or SBAA. All patients in this trial, irre-
spective of their group assignment, will receive guide-
line-based, state-of-the-art maintenance treatment. The 
treating psychiatrist will be expected to contact the par-
ticipant and judge whether an intervention or adaptation 
of medication is required.
Regarding the primary endpoint, survival analysis 
(Kaplan–Meier estimators) will be used for estimating 
time to a new affective episode. Log-Rank tests will be 
used for group comparisons. All patients who have been 
randomized will be included in the statistical analyses. 
For secondary endpoints, two separate survival analyses 
will be applied to compare the time to a new depressive 
and (hypo)manic episode, respectively. Wilcoxon-tests 
for independent samples (SBAA+ vs SBAA) will be used 
to test for differences in (1) the percentages of assess-
ments meeting the diagnostic criteria, (2) the percentages 
of assessments hospitalized, (3) the severity of manic 
symptoms, and (4) the severity of depressive symptoms. 
The frequencies of adverse events will be compared using 
Fisher’s exact test. The sample size of n = 60 per group 
was determined from a power calculation for survival 
analysis with constant hazard and drop-out rates. The 
relapse rate under SBAA (control condition) was esti-
mated from the patient data from our bipolar disorders 
outpatient clinic Accordingly, we expect a monthly haz-
ard rate of about 6% which corresponds to a relapse rate 
of 66% during the observation period of 18 months. From 
our experience with similar patients from other studies 
we further expect a monthly drop-out rate of about 2.5% 
which corresponds to a drop-out rate of 37% during the 
observation period. The hazard ratio was supposed to be 
about 0.5.
If shown to be beneficial, ambulatory monitoring may 
become a further pillar in the maintenance treatment of 
bipolar disorder for those who choose to use a smart-
phone (Table 1).
Neuroimaging markers for the prediction of lithium 
treatment effects in a suicidal depressive episode 
of bipolar disorder (Project B2)
Lithium is an established substance for the prevention 
of suicide in affective disorders (Lewitzka et  al. 2015b). 
It remains uncertain, however, whether these effects can 
also be observed in the short-term treatment of acutely 
suicidal patients. Within a separate multicenter, double-
blind, randomized controlled trial investigating the effect 
of lithium in addition to TAU in affectively ill patients 
with acute suicidality over 5 weeks (Lewitzka et al. 2015a), 
a neuroimaging study will aim to describe the neural cor-
relates of lithium treatment on suicidality. Furthermore, 
the project aims to identify neuroimaging markers that 
are associated with and may be predictive of treatment 
response with lithium. Participants will receive an fMRI 
prior to and following the 5 week intervention. The neu-
roimaging study will be carried out at five sites within the 
consortium and aims to recruit a total of 80 participants. 
If successful, neuroimaging data may in future assist in 
more rational therapeutic decision-making.
Genomic and transcriptomic biomarkers for predicting 
lithium treatment response in bipolar disorder (Project B3)
Lithium remains the mainstay of treatment in bipolar dis-
order (Nolen 2015; Severus et al. 2014). Although a sub-
stantial number of patients respond excellently to lithium 
monotherapy, this is not true for all (Kessing et al. 2011). 
Currently, there are no reliable biomarkers which could 
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predict lithium response, leaving physician and patient 
to establish the suitable treatment by trial and error. This 
project aims to delineate a “lithium predictor tool set” 
integrating information from genome-wide association 
study (GWAS) data and transcriptomic analyses.
Using the already available unique phenotype and 
biobank resource of the Consortium on Lithium Genet-
ics (http://www.ConLiGen.org), lymphoblastoid cell 
lines (LCLs) from 75 lithium responders (R) and 75 non-
responders (R) BD patients will be investigated by the 
use of genome-wide expression profiling of genes and 
miRNAs. Applying a replication design, an exploratory 
analysis comparing LCLs from 30 R and 30 NR patients 
will be performed first. Best results will be followed up 
in the remaining 45 R and 45 NR individuals. Analyses 
will be performed using real-time PCR for the top genes 
and miRNAs from the exploratory part. We will apply a 
cutoff value of a 1.5-fold difference between the groups 
at p  <  0.001. Cellular drug effects will be studied, using 
lithium-mediated growth inhibition that will be corre-
lated to clinical response and gene expression profiling in 
LCLs from the patient sample characterized for lithium 
response and control individuals. Using state-of-the art 
bioinformatics approaches, the project will be the first to 
combine information obtained from GWAS and expres-
sion profiling to define a set of genomic predictors of lith-
ium response. This may develop to become a future tool 
for a more personalized treatment approach to mood sta-
bilization in BD.
Neuroimaging, neurophysiology, biobanking, 
and data‑management infrastructure (Projects TPP1 
and TPP2)
Within a research network of this size conventional 
methods of data acquisition (i.e., paper and pencil), 
storage (i.e., local hard drive or server), and process-
ing (i.e., spreadsheet) would be inadequate, slow, and 
unsafe. In addition, the requirements of funding bod-
ies, ethics committees, and regulatory authorities 
are becoming ever more rigorous. These challenging 
demands will be met by a centralized framework for 
highly encrypted proband and identity management; 
flexible and swift storage, retrieval and exchange of 
data, and biomaterial. Data acquisition will occur at 
all sites via a browser-based interface using SecuTrial 
(http://www.secutrial.com) software. The data storage 
will be managed by the medical informatics section 
of Göttingen University. Biomaterials will be acquired 
using consortium-wide SOPs and protocols and all 2D 
barcoded material will be stored at two mirrored sites 
in Gottingen and Würzburg for genomic, transcrip-
tomic, and proteomic analyses.
Acquiring neuroimaging data from nine different sites 
requires the harmonization of protocol, standardization 
of paradigms, and regular quality control to detect and 
combat local signal-aberrations early (Hellerbach et  al. 
2013). All participants opting for the additional neuroim-
aging study within A1, A2 or B2 will receive an identical 
battery including:
Table 1 Methods, study populations, and design within the structure of the BipoLife consortium
Bipolife 
project












✓ ✓ ✓ ✓
A2 Trial of specific group 
psychotherapy for 
bipolar disorder
Young patients with 










Patients with a highly 
recurrent/unstable 
course of BD




B2 Neuroimaging study 












eomic markers of 
lithium response
BD patients with 
lithium response vs. 
non response
150 Cross-sectional ✓ ✓
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i. T1-sequence for morphometric analyses
ii. T2-sequence for investigating the hippocampus on a 
subregional level
iii. Resting-state fMRI sequence and three fMRI activa-
tion paradigms
iv. Highly robust emotional face matching paradigm 
for assessing limbic responsiveness to negative facial 
expressions (Dannlowski et al. 2012).
v. Cartoon Theory-of-Mind task which robustly acti-
vates the theory of mind (ToM) network relevant 
for social cognition, since a dysfunction of the ToM 
network activated by this task is associated with a 
genetic risk variant for BD and in relatives of patients 
with BD (Walter et al. 2011).
vi. Desire-reason dilemma task using conditioned 
reward stimuli in different experimental situations, 
thereby allowing the investigation of subcortical 
structures of the dopaminergic reward system and 
their specific functional interactions with prefrontal 
cortices (Diekhof and Gruber 2010).
An EEG battery focusing on neural synchrony in long-
range and local oscillatory responses will include cogni-
tive (choice-reaction tasks), perceptive (Kanizsa figures), 
and emotional (emotional faces) paradigms (Özerdem 
et al. 2011), complementing the MRI data.
Conclusions
The German BipoLife consortium consists of a nation-
wide network of university centers aiming to address 
unanswered questions in the early recognition, reliable 
diagnosis, rational treatment, and prognosis of bipo-
lar disorder. By utilizing a centralized secure IT-infra-
structure, the consortium aims to minimize incomplete 
data and provide safe and rapid access for analyses (i.e., 
interim analysis). The consortium hopes to establish fluid 
and neuroimaging biomarkers to improve rational treat-
ment decisions and support the estimation of prognosis. 
The studies will hopefully also encourage more effective 
ways of early warning sign detection and more conveni-
ent delivery of psychotherapeutic care.
The structure of the gathered data will deliver the 
opportunity for complex secondary analyses, combining 
highly detailed phenotypic, neuroimaging, genomic, and 
transcriptomic information.
The crucial aim within the BipoLife consortium is to lay 
the foundation for a contemporary research infrastruc-
ture specific for bipolar disorder and the network part-
ners will campaign to secure a more permanent funding.
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